Your browser doesn't support javascript.
loading
Long term outcomes of nonmyeloablative allogeneic stem cell transplantation with TSEB TLI and ATG for Mycosis Fungoides and Sezary Syndrome.
Morris, S L; Thomas, B R; Palanicawandar, R; Whittaker, S; Child, F; Wain, M; Sim, V; Szydlo, R; Mangar, S; Olavarria, E; Lozano Cerrada, S; Muzamil, A; Kanfer, E.
Affiliation
  • Morris SL; Guys Hospital, London, UK. Stephen.morris@gstt.nhs.uk.
  • Thomas BR; Guys Hospital, London, UK.
  • Palanicawandar R; Hammersmith Hospital, London, UK.
  • Whittaker S; Guys Hospital, London, UK.
  • Child F; Guys Hospital, London, UK.
  • Wain M; Guys Hospital, London, UK.
  • Sim V; Guys Hospital, London, UK.
  • Szydlo R; Hammersmith Hospital, London, UK.
  • Mangar S; Hammersmith Hospital, London, UK.
  • Olavarria E; Hammersmith Hospital, London, UK.
  • Lozano Cerrada S; Hammersmith Hospital, London, UK.
  • Muzamil A; Hammersmith Hospital, London, UK.
  • Kanfer E; Hammersmith Hospital, London, UK.
Bone Marrow Transplant ; 59(6): 874-879, 2024 Jun.
Article de En | MEDLINE | ID: mdl-38472408
ABSTRACT
Advanced stage (IIB-IVB) Mycosis Fungoides (MF) and Sezary Syndrome (SS) have a poor prognosis with median survival <5 years. We report long-term outcomes of a non-myeloablative allogeneic stem cell transplantation regimen consisting of total skin electron beam therapy, total lymphoid irradiation and antithymocyte globulin. Our prospective cohort consisted of 41 patients with a higher proportion of MF (34MF, 7SS). Acute GVHD Grade 2 to 4 was seen in 31.7% and chronic GVHD Grade 2 to 4 in 24%. The cumulative incidence of non-relapse mortality was 9.8% at 1 year and 12.6% at 2 years. At Day +90 post-transplant 66% of patients had a complete response (CR). With a median post-transplant follow up of 5.27 years, the 5-year overall survival rate was 37.7% (MF 36.7%, SS 57.1%). The 5-year cumulative incidence of progressive disease or relapse was 52.7% in all patients but only 20.8% in those with CR at transplant compared to 70.6% in those not in CR at transplant (p = 0.006). Long term survival is possible in advanced MF and SS with non-myeloablative transplantation and outcomes are improved in patients with CR at transplant.
Sujet(s)

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Mycosis fongoïde / Syndrome de Sézary Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Bone Marrow Transplant Sujet du journal: TRANSPLANTE Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Royaume-Uni

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Mycosis fongoïde / Syndrome de Sézary Limites: Adult / Aged / Female / Humans / Male / Middle aged Langue: En Journal: Bone Marrow Transplant Sujet du journal: TRANSPLANTE Année: 2024 Type de document: Article Pays d'affiliation: Royaume-Uni Pays de publication: Royaume-Uni